AFP and hepatocellular carcinoma: Needs more clinicalvalidation; 95% and 71% of patients hadpositive values of %AFP-L3 at 3 and 6 months before diagnosis, respectively;sub-optimal in terms of cost-effectiveness for routine surveillanceof early HCC